Alcon seen valued up to $25 billion in biggest Swiss stock deal in decade – Investing.com UK

This post was originally published on this site

https://lh5.googleusercontent.com/proxy/9CaWJSb5yVAZ7hkZjPf402ELyOruCunScd7REhDmg6alY_lORCOEtOev1QjtBADj3kPUmReVgmpy4aZ3GC5ARuK3paVHz432hKgDfkk=-w150-h150-c
© Reuters. Alcon seen valued up to $25 billion in biggest Swiss stock deal in decade

ZURICH (Reuters) – Swiss eyecare company Alcon is set to be valued up to $25 billion (£19 billion) on its first day of trading on Tuesday, making it the biggest Swiss stock market transaction in a decade following its spin-off from drugmaker Novartis to shareholders.

The shares were seen trading between 46.45 Swiss francs per share and 53.45 francs per share, according to premarket indicators, roughly in line with analyst and the company’s expectations.

Novartis shares were seen falling around 9 percent as its eyecare unit with $7.1 billion in annual sales is carved off into a separate company.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

This post was originally published on *this site*